[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2013004315A - Metodos y composiciones para modular la ruta wnt. - Google Patents

Metodos y composiciones para modular la ruta wnt.

Info

Publication number
MX2013004315A
MX2013004315A MX2013004315A MX2013004315A MX2013004315A MX 2013004315 A MX2013004315 A MX 2013004315A MX 2013004315 A MX2013004315 A MX 2013004315A MX 2013004315 A MX2013004315 A MX 2013004315A MX 2013004315 A MX2013004315 A MX 2013004315A
Authority
MX
Mexico
Prior art keywords
modulating
compositions
methods
wnt pathway
sost
Prior art date
Application number
MX2013004315A
Other languages
English (en)
Inventor
Eric Bourhis
Andrea Cochran
Yingnan Zhang
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2013004315A publication Critical patent/MX2013004315A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La invención proporciona métodos y composiciones para modular la ruta de señalización Wnt, en particular al interferir con enlace de Dkk1 o SOST con LRP5 y/o LRP6.
MX2013004315A 2010-10-20 2011-10-19 Metodos y composiciones para modular la ruta wnt. MX2013004315A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39484010P 2010-10-20 2010-10-20
PCT/US2011/056826 WO2012054565A1 (en) 2010-10-20 2011-10-19 Methods and compositions for modulating the wnt pathway

Publications (1)

Publication Number Publication Date
MX2013004315A true MX2013004315A (es) 2013-07-17

Family

ID=44903414

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013004315A MX2013004315A (es) 2010-10-20 2011-10-19 Metodos y composiciones para modular la ruta wnt.

Country Status (13)

Country Link
US (2) US20120100562A1 (es)
EP (1) EP2630154A1 (es)
JP (1) JP2013544798A (es)
KR (1) KR20140001216A (es)
CN (1) CN103270045A (es)
AU (1) AU2011317182A1 (es)
BR (1) BR112013008031A2 (es)
CA (1) CA2812785A1 (es)
IL (1) IL225391A0 (es)
MX (1) MX2013004315A (es)
RU (1) RU2013122801A (es)
SG (1) SG189271A1 (es)
WO (1) WO2012054565A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013527762A (ja) 2010-05-06 2013-07-04 ノバルティス アーゲー 治療的低密度リポタンパク質関連タンパク質６（ｌｒｐ６）抗体の組成物および使用方法
SG185415A1 (en) 2010-05-06 2012-12-28 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
JP2015502741A (ja) 2011-11-04 2015-01-29 ノバルティス アーゲー 低比重リポタンパク質関連タンパク質６（ｌｒｐ６）−半減期延長構築物
WO2015196070A1 (en) 2014-06-20 2015-12-23 Genentech, Inc. Chagasin-based scaffold compositions, methods, and uses
KR20180002758U (ko) 2017-03-16 2018-10-01 권영준 카드 수납형 휴대폰 케이스
TWI698250B (zh) * 2018-12-20 2020-07-11 三凡生技研發股份有限公司 短鏈胜肽組合物於預防或治療乾眼症之應用
TWI698249B (zh) * 2018-12-27 2020-07-11 三凡生技研發股份有限公司 短鏈胜肽組合物於保護眼睛抗光害之應用
AU2020274530A1 (en) * 2019-05-15 2021-12-16 Whitehead Institute For Biomedical Research Methods of characterizing and utilizing agent-condensate interactions
KR102192471B1 (ko) * 2019-10-18 2020-12-17 주식회사 인코스팜 탈모 완화 및 모발 성장을 촉진시키는 펩타이드 및 이를 포함하는 화장료 조성물
WO2021087031A1 (en) * 2019-10-29 2021-05-06 Acworth Pharmaceuticals, Inc. Peptide mimetics of dkk3b and methods of use
US11572394B2 (en) * 2020-02-16 2023-02-07 Pasteur Institute Of Iran Peptides for targeting LRP6-overexpressed cells

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0429537A4 (en) 1988-08-18 1991-08-21 California Biotechnology, Inc. Atrial natriuretic peptide clearance inhibitors
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
AU2002318112B2 (en) * 2001-04-10 2007-12-06 Agensys, Inc. Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
US20040038860A1 (en) * 2002-05-17 2004-02-26 Allen Kristina M. Reagents and methods for modulating dkk-mediated interactions
WO2003106657A2 (en) * 2002-06-14 2003-12-24 Stowers Institute For Medical Research Wise/sost nucleic acid sequences and amino acid sequences
WO2008031009A2 (en) 2006-09-08 2008-03-13 Genentech, Inc. Wnt antagonists and their use in the diagnosis and treatment of wnt-mediated disorders
JP6093692B2 (ja) 2010-03-24 2017-03-08 ジェネンテック， インコーポレイテッド 抗ｌｒｐ６抗体

Also Published As

Publication number Publication date
SG189271A1 (en) 2013-05-31
CN103270045A (zh) 2013-08-28
JP2013544798A (ja) 2013-12-19
KR20140001216A (ko) 2014-01-06
AU2011317182A1 (en) 2013-04-11
RU2013122801A (ru) 2014-11-27
BR112013008031A2 (pt) 2019-09-24
IL225391A0 (en) 2013-06-27
US20120100562A1 (en) 2012-04-26
US20140235820A1 (en) 2014-08-21
WO2012054565A1 (en) 2012-04-26
CA2812785A1 (en) 2012-04-26
EP2630154A1 (en) 2013-08-28

Similar Documents

Publication Publication Date Title
MX2013004315A (es) Metodos y composiciones para modular la ruta wnt.
ZA201300319B (en) Compositions and methods for modulating the wnt signaling pathway
WO2012140274A3 (en) Agonists and antagonists of the wnt pathway
MX345909B (es) Anticuerpos anti-fgfr3 y métodos que los utilizan.
EA201591474A1 (ru) Модуляторы метил-модифицирующих ферментов, композиции и их применение
MX2013015311A (es) Polipeptidos de enlace de pcsk9 y metodos de uso.
UA116091C2 (uk) Способи та композиції для боротьби з бур'янами
UA116092C2 (uk) Спосіб та композиція для боротьби з бур'янами (варіанти)
PH12015502401A1 (en) Compositions and methods for enhancing microbial stability
EP2569330A4 (en) CHLOROTOXINE VARIANTS, CONJUGATES, AND METHODS OF USE THEREOF
UA116196C2 (uk) Синтетичний міметик апеліну для лікування серцевої недостатності
GB201308243D0 (en) High-throughput immune sequencing
EP2532688A4 (en) (CO) ALPHA-OLEFIN POLYMER, (CO) HYDROGENATED ALPHA-OLEFIN POLYMER AND LUBRICATING OIL COMPOSITION CONTAINING SAME
EP4023243A3 (en) Compositions and methods for treating celiac sprue disease
MX2015007778A (es) Prediccion de bioactivacion molecular.
MX359181B (es) Hidrolizado de colágeno y uso del mismo.
UY34575A (es) Composiciones y métodos para el tratamiento de diabetes y/u obesidad
PH12015501099A1 (en) Synbiotic composition and use thereof
WO2014093988A3 (en) Methods and compositions for inhibiting cnksr1
WO2010007175A3 (en) Pacap signaling pathway modulators for treating inflammatory skin diseases with a neurogenic component, and more particularly rosacea and composition containing them
ECSP13012679A (es) Composiciones farmacéuticas que comprenden alisporivir
IN2012DN01379A (es)
GT200900042S (es) Cubierta de recipiente de comida.
WO2011014872A3 (en) Compositions and methods for diagnosing, treating or preventing neoplasias
EA201071163A1 (ru) Применение дефенсинов против менингита

Legal Events

Date Code Title Description
FA Abandonment or withdrawal